Excellence in Dermatology™
Excellence in Dermatologic Surgery™
Excellence in Medical Dermatology™
Excellence in Dermatopathology™

Search Results

Your search for the word "dupilumab" returned 37 results
1 - 15 of 37 Content Items

Dupilumab: The first year

February 27, 2019
When introduced as dermatologist to a new acquaintance, I'm sure you have heard: —œDermatology is a great field —" you don't cure anybody, so they keep coming back!—Trust me. It's no joy to see patients with recalcitrant, severe, life-altering, debilitating diseases such as atopic dermatitis, psoriasis, recalcitrant mycosis fungoides, et cetera, express their frustration, anxiety, and depression, when therapeutic interventions have failed. ... Issue | DW Archive | DW Weekly | DW Insights & Inquiries Dupilumab: The first year By Warren R. Heymann, MD Jan. 8, 2018 A patient with severe atopic dermatitis has benefited from dupilumab

Dupilumab’s conjunctivitis conundrum

February 11, 2019
Having worn glasses since kindergarten, and being virtually helpless without them, I am particularly sympathetic to patients with eye disorders. ... and, and infectious keratoconjunctivitis may complicate therapy with corticosteroids. Dupilumab may cause... was recently reviewed in DI&I (January 8, 2018). ... In two phase 3 trials of dupilumab versus

How does dupilumab perform in the long term?

November 1, 2017
Physician Editor Abby Van Voorhees, MD, talks with Andrew Blauvelt, MD, MBA, about his recent Lancet article. ... Lancet article, " Long-term management of moderate-to-severe atopic dermatitis with dupilumab...? How was this study different from the phase 3 trial for dupilumab that had only a placebo arm? Why

Dupilumab and the dawn of the biologic era for atopic dermatitis

February 20, 2019
I have a list of patients with severe, recalcitrant atopic dermatitis (AD) eagerly awaiting the release of dupilumab. I first became aware of this biologic from the article by Beck et al, who noted that dupilumab, a fully humanized monoclonal antibody that blocks IL-4 and IL-13, previously reported to be efficacious in patients with asthma and eosinophilia, could also be beneficial for atopic dermatitis. ... the release of dupilumab. I first became aware of this biologic from the article by Beck et al, who noted that dupilumab, a fully humanized monoclonal antibody that blocks IL-4 and IL-13, previously reported

Does dupilumab pass the test for atopic dermatitis?

January 1, 2017
Physician Editor Abby Van Voorhees, MD, talks with Eric L. Simpson, MD, MCR about his recent New England Journal of Medicine article. ... New England Journal of Medicine article, " ... Two Phase 3 Trials of Dupilumab versus Placebo...: Dupilumab is a biologic agent. Let’s review its target and how it is presumed to work. Has it previously

Angiolymphoid hyperplasia with eosinophila and kimura disease: Dupilumab beckons

March 3, 2019
Controversy should be the middle name for angiolymphoid hyperplasia with eosinophilia (ALHE) and Kimura disease (KD). Throughout my career, I have read about these diseases, wondering why they were initially considered related entities but now viewed as distinct. ... radiation and cytotoxic agents have been utilized (2). ... Dupilumab (Dupixent), the anti-IL-4/IL-13... to try it for KD and recalcitrant cases of ALHE. To date there are no such reports utilizing dupilumab

September 26

May 3, 2019
after shortages September Access Hero: Dr. Jonathan Silverberg Dupilumab improves adolescent atopic... product: Simulated Patient Encounter – Medication Management Dupilumab improves adolescent

Filling the medicine cabinet

August 1, 2018
Dupilumab and crisaborole could be just the start of an atopic dermatitis treatment revolution. ... of stinging and burning at the application site, where does dupilumab stand in the pediatric space...Back to current issue Menu ... Dupilumab and crisaborole have changed atopic dermatitis treatment

Atopic dermatitis: Fantasizing about a dual approach

March 4, 2019
It has been acknowledged that we are on the cusp of biologic therapy for atopic dermatitis. My cadre of patients with severe atopic dermatitis (AD) are itching for its release —" whenever that will be. Is there another pathway to alleviate pruritus? The itch meisters point to IL-31 as a factor. ... Patient photos before and after dupilumab. A, Subject-provided photograph before the start of dupilumab therapy. B, Photograph taken in the clinic 1 year after the patient started dupilumab therapy

Ustekinumab: A topic for atopics?

March 5, 2019
If you're like me, you have a cadre of patients with severe atopic dermatitis (AD) patients who are counting the minutes for the release of dupilimab (a human monoclonal antibody against interleukin-4 receptor alpha, that inhibits signaling of interleukin-4 and interleukin-13, type 2 cytokines that may be important drivers of atopic or allergic diseases such as atopic dermatitis). ... phase 3 trials of identical design involving patients with atopic dermatitis, dupilumab improved..., and quality of life, as compared with placebo (1). ... While I certainly hope that dupilumab

2 FDA-approved medications increase treatment options for eczema

March 15, 2018
Two FDA-approved medications are giving people who have eczema more treatment options. ... for this medication is dupilumab (do-pill-you-mab). It’s considered a breakthrough treatment..., another common skin disease. ... We still don’t know whether dupilumab can be safely taken

Playing the angles

December 1, 2016
New treatments target potential pathways for atopic dermatitis. ... to effective disease control." ... Dupilumab – Interleukin (IL) 4/IL-13 Dupilumab is often the first biologic that comes to mind for atopic dermatitis. "Dupilumab really represents a potential paradigm

November 28

December 3, 2018
to the supplemental Biologics License Application (sBLA) of dupilumab (Dupixent) to treat moderate... by phase 3 trial data indicating that dupilumab significantly improves symptoms in adolescents

What's hot?

June 1, 2017
Members of DW's Editorial Advisory Workgroup share exciting news from across the specialty. ... Aldredge, MSN, ANP-BC ... Well, it’s finally here! ... On March 28, the FDA approved dupilumab (Dupixent... and efficacy of dupilumab were established in three placebo-controlled clinical trials with a total of 2,119

From the editor

August 1, 2018
Physician Editor Kathryn Schwarzenberger, MD, discusses the exciting content in the August 2018 issue of Dermatology World. ... the IL-13/IL-4 inhibitor dupilumab, and other novel treatments are in the pipeline. I am personally
1 - 15 of 37 Content Items